Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Compass Therapeutics Inc (NASDAQ: CMPX) closed at $5.53 in the last session, down -0.18% from day before closing price of $5.54. In other words, the price has decreased by -$0.18 from its previous closing price. On the day, 1.13 million shares were traded. CMPX stock price reached its highest trading level at $5.74 during the session, while it also had its lowest trading level at $5.48.
Ratios:
We take a closer look at CMPX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 17.82 and its Current Ratio is at 17.82. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Citizens JMP on December 03, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $10.
On December 03, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $10.Canaccord Genuity initiated its Buy rating on December 03, 2025, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 27 ’25 when Schuetz Thomas J. bought 10,000 shares for $2.11 per share. The transaction valued at 21,100 led to the insider holds 6,480,825 shares of the business.
GORDON CARL L sold 3,571,428 shares of CMPX for $5,678,571 on Apr 09 ’25. The Director now owns 0 shares after completing the transaction at $1.59 per share. On Apr 09 ’25, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 3,571,428 shares for $1.59 each. As a result, the insider received 5,678,571 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CMPX now has a Market Capitalization of 983577408 and an Enterprise Value of 773549440.
Stock Price History:
The Beta on a monthly basis for CMPX is 1.26, which has changed by 2.351515 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, CMPX has reached a high of $5.86, while it has fallen to a 52-week low of $1.33. The 50-Day Moving Average of the stock is 26.55%, while the 200-Day Moving Average is calculated to be 82.76%.
Shares Statistics:
According to the various share statistics, CMPX traded on average about 1.85M shares per day over the past 3-months and 2204960 shares per day over the past 10 days. A total of 177.57M shares are outstanding, with a floating share count of 122.34M. Insiders hold about 31.21% of the company’s shares, while institutions hold 61.21% stake in the company. Shares short for CMPX as of 1763078400 were 16608425 with a Short Ratio of 8.98, compared to 1760486400 on 15358838. Therefore, it implies a Short% of Shares Outstanding of 16608425 and a Short% of Float of 14.760000000000002.
Earnings Estimates
The stock of Compass Therapeutics Inc (CMPX) is currently in the spotlight, with 11.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.08 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.36 and -$0.5 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.42, with 11.0 analysts recommending between -$0.21 and -$0.6.
Revenue Estimates
Based on 13 analysts’ estimates, the company’s revenue will be $3.07M in the next fiscal year. The high estimate is $39.32M and the low estimate is -$36M.
